Us TOO Advocacy Alert  
September 24, 2010

From: Thomas Kirk, President and CEO

Subject: Sign petition for Medicare coverage of FDA-approved prostate cancer treatments by Nov 5

Sign online petition NOW or Print petition form

Dec 13, 2010 update: Thanks to all your support, we’ve collected more than 4,500 signatures so far! Now that the MEDCAC meeting has been held, we await their decision. We’ll keep you posted.

I am asking the Us TOO network of survivors, family members and support group chapters to raise your voices in support of Medicare reimbursement for FDA approved cancer drugs. 

On April 29, 2010, the U.S. Food and Drug Administration approved Provenge for the treatment of men with asymptomatic or minimally symptomatic metastatic, castrate resistant (hormone refractory) prostate cancer. 

We celebrated the new treatment option for men with advanced disease. But now there is a problem.

Dr. Mark Moyad has brought to our attention that the agency that oversees Medicare coverage, the Centers for Medicare and Medicaid Services (CMS), wants to review the appropriateness of covering this new prostate cancer treatment.

We believe that if the FDA approves a treatment option, that Medicare and insurance companies should provide unrestricted access and coverage for it!

Dr. Mark Moyad has challenged us to act, and along with other patient advocates, has created a petition that he would like Us TOO and other prostate cancer organizations to circulate.

Please participate in this national grass roots campaign by signing the petition TODAY! Collect additional signatures from your family members, friends, co-workers and at your next local Us TOO support group chapter meeting.

The goal is to collect thousands of signatures from across the country, so we can present them at the CMS public meeting in Baltimore on Wednesday, November 17, 2010.

The meeting will be conducted by the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) of the Centers for Medicare & Medicaid Services (CMS). Discussion will focus on the currently available evidence regarding the clinical benefits and harms of on-label and off-label use of Autologous Cellular Immunotherapy Treatment of Metastatic Prostate Cancer (aka Provenge), and if it is adequate for the Committee to advise that the treatment costs be covered by Medicare. This meeting is open to the public and will also be broadcast via a Webinar. You must register for the Webinar portion of the meeting by 5 pm EST, Wed, Nov 10, 2010. 

Register for the live MEDCAC webinar here


Mail or fax signed and completed petition pages by November 5, 2010 to:

Tom Kirk, President & CEO
Us TOO International
5003 Fairview Ave.
Downers Grove, IL, 60515

Fax: 630-795-1602

Contact Tom Kirk at or 630-795-1002

Tips for communicating with elected officials | Find your U.S. Senators | Find your U.S. Representatives | Return to Us TOO Advocacy Program page

Facebook -  Twitter -  LinkedIn - Inspire prostate cancer discussions – 

Contact Us | Privacy Policy | Terms & Conditions | Disclaimer   

Copyright © 2005-2014 Us TOO International, Inc.
Designed and hosted by ACCESS Medical Group, Ltd.